Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pozelimab + cemdisiran versus cemdisiran alone versus placebo in symptomatic generalized myasthenia gravis
CTR20241295Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pozelimab, cemdisiran in myasthenia gravis (MG), sponsored by Regeneron Pharmaceuticals. Started Aug 2024; status: active.
02
Drugs
pozelimabcemdisiran
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20241295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241295.